Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 3c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• AppLovin drops 3% as Edgewater analyst warns of stalled market share growth